Sangamo jumps as US FDA fast-tracks drug for chronic nerve pain

Shares of drug developer Sangamo Therapeutics SGMO.O rise 6% to $0.47

Co says U.S. FDA granted fast-track designation to its experimental treatment, ST-503, for a severe form of chronic nerve pain

ST-503 is experimental epigenetic regulator aimed at providing non-opioid treatment options, co says

U.S. FDA's "fast track" tag aims to speed development and review of drugs for serious conditions with unmet medical needs

Co expects to dose first patient in its early-stage trial in coming months - SGMO

Including session's move, stock down ~56% YTD